{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:34:23Z","timestamp":1793090063964,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009076","name":"USTC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105553","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:53:04Z","timestamp":1787295184000},"page":"105553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["CAR-T cell therapy-associated coagulopathy: From immunothrombotic storm mechanisms to precision management strategies"],"prefix":"10.1016","volume":"227","author":[{"given":"Buyi","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingbing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105553_bib1","doi-asserted-by":"crossref","first-page":"L1232","DOI":"10.1152\/ajplung.00109.2006","article-title":"TNF-alpha increases tyrosine phosphorylation of vascular endothelial cadherin and opens the paracellular pathway through fyn activation in human lung endothelia","volume":"291","author":"Angelini","year":"2006","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.critrevonc.2026.105553_bib2","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.3390\/cancers17213551","article-title":"High rate of cytokine release syndrome-related coagulopathy with low incidence of bleeding and thrombosis in patients treated with B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cells (CAR-T)","volume":"17","author":"Arad","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105553_bib3","doi-asserted-by":"crossref","first-page":"805","DOI":"10.7326\/M19-1795","article-title":"Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the international consensus group","volume":"171","author":"Barkun","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.critrevonc.2026.105553_bib4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105553_bib5","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00277-022-04889-6","article-title":"Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells-single-center experience","volume":"101","author":"Beyar-Katz","year":"2022","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105553_bib6","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1182\/bloodadvances.2020002757","article-title":"Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy","volume":"5","author":"Buechner","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105553_bib7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/ejh.14099","article-title":"Application of thromboelastography to predict the severity of bleeding after chimeric antigen receptor (CAR)-T cell therapy in patients with hematological malignancy","volume":"112","author":"Chen","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2026.105553_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115973","article-title":"CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients","volume":"44","author":"Cook","year":"2025","journal-title":"Cell. Rep."},{"key":"10.1016\/j.critrevonc.2026.105553_bib9","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.3390\/cancers15225443","article-title":"Population-based external validation of the EASIX scores to predict CAR T-cell-related toxicities","volume":"15","author":"de Boer","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105553_bib10","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.3390\/cancers17172876","article-title":"Endothelial injury following CAR-T cell immunotherapy for hematological malignancies","volume":"17","author":"Demosthenous","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105553_bib11","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/bloodadvances.2022008066","article-title":"Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists","volume":"7","author":"Drillet","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105553_bib12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41569-018-0064-2","article-title":"Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty","volume":"15","author":"Ferrucci","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.critrevonc.2026.105553_bib13","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1182\/bloodadvances.2023010728","article-title":"Longitudinal plasma proteomics in CAR T-cell therapy patients implicates neutrophils and NETosis in the genesis of CRS","volume":"8","author":"Flora","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105553_bib14","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.3390\/jcm14144926","article-title":"Venous thromboembolic events in cancer immunotherapy: a narrative review","volume":"14","author":"Fowler","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.critrevonc.2026.105553_bib15","first-page":"149","article-title":"Prothrombin complex concentrates: an update","volume":"8","author":"Franchini","year":"2010","journal-title":"Blood Transfus."},{"key":"10.1016\/j.critrevonc.2026.105553_bib16","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/bloodadvances.2022008042","article-title":"Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA\/DRST study","volume":"7","author":"Gagelmann","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105553_bib17","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjh.18596","article-title":"Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells","volume":"201","author":"Galli","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2026.105553_bib18","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105553_bib19","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105553_bib20","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105553_bib21","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/QCO.0000000000000679","article-title":"Infections after anti-CD19 chimeric antigen receptor T-cell therapy for hematologic malignancies: timeline, prevention, and uncertainties","volume":"33","author":"Haidar","year":"2020","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.critrevonc.2026.105553_bib22","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/bloodadvances.2020002060","article-title":"Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma","volume":"4","author":"Hashmi","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105553_bib23","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105553_bib24","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.critrevonc.2026.105553_bib25","article-title":"Rediscovering hemostasis abnormalities in multiple myeloma: the new era","volume":"10","author":"Huang","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.critrevonc.2026.105553_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017046","article-title":"New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey","volume":"7","author":"Iba","year":"2017","journal-title":"BMJ Open."},{"key":"10.1016\/j.critrevonc.2026.105553_bib27","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00277-019-03685-z","article-title":"Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy","volume":"98","author":"Jiang","year":"2019","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105553_bib28","first-page":"1049","article-title":"Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105553_bib29","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.it.2021.06.001","article-title":"The 'cytokine storm': molecular mechanisms and therapeutic prospects","volume":"42","author":"Karki","year":"2021","journal-title":"Trends Immunol."},{"key":"10.1016\/j.critrevonc.2026.105553_bib30","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105553_bib31","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2026.105553_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2025.109527","article-title":"Bone marrow blasts- and modified EASIX-guided risk stratification for coagulopathy and outcomes after CAR-T therapy in relapsed\/refractory B-ALL","volume":"256","author":"Li","year":"2025","journal-title":"Thromb. Res."},{"key":"10.1016\/j.critrevonc.2026.105553_bib33","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/bloodadvances.2024014455","article-title":"Development and validation of predictive models of early immune effector cell-associated hematotoxicity","volume":"9","author":"Liang","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105553_bib34","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1055\/s-0036-1571311","article-title":"Diagnostics of inherited bleeding disorders of secondary hemostasis: an easy guide for routine clinical laboratories","volume":"42","author":"Lippi","year":"2016","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.critrevonc.2026.105553_bib35","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/hon.3155","article-title":"A comprehensive analysis of coagulopathy during anti-B cell maturation antigen chimeric antigen receptor-T therapy in multiple myeloma, a retrospective study based on LEGEND-2","volume":"41","author":"Liu","year":"2023","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105553_bib36","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105553_bib37","doi-asserted-by":"crossref","first-page":"248","DOI":"10.11613\/BM.2016.028","article-title":"Interference of M-protein on prothrombin time test \u2013 case report","volume":"26","author":"Margeti\u0107","year":"2016","journal-title":"Biochem. Med."},{"key":"10.1016\/j.critrevonc.2026.105553_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for immunotherapy of cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105553_bib39","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1097\/CM9.0000000000002288","article-title":"Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathy","volume":"135","author":"Mei","year":"2022","journal-title":"Chin. Med. J. (Engl. )"},{"key":"10.1016\/j.critrevonc.2026.105553_bib40","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1055\/a-2215-9909","article-title":"Update on thrombosis risk in patients with cancer: focus on novel anticancer immunotherapies","volume":"44","author":"Moik","year":"2024","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.critrevonc.2026.105553_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006365","article-title":"Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis","volume":"11","author":"Moreno-Casta\u00f1o","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105553_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1699894","article-title":"Endothelial dysfunction and hemostatic imbalance in CAR T-cell-associated toxicities: pathophysiological insights and the role of circulating biomarkers","volume":"16","author":"Moreno-Casta\u00f1o","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105553_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1654096","article-title":"Macrophage activation syndrome-like in multiple myeloma patients treated with the academic CAR-T against BCMA ARI0002h","volume":"16","author":"Mun\u00e1rriz","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105553_bib44","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105553_bib45","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41409-025-02567-5","volume":"60","author":"Ort\u00ed","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2026.105553_bib46","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/7020539","article-title":"Thromboelastography and thromboelastometry in assessment of fibrinogen deficiency and prediction for transfusion requirement: a descriptive review","volume":"2018","author":"Peng","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.critrevonc.2026.105553_bib47","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105553_bib48","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.3324\/haematol.2023.284564","article-title":"Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"109","author":"Perl","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2026.105553_bib49","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105553_bib50","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/hematology.2023000472","article-title":"Recognizing, defining, and managing CAR-T hematologic toxicities","volume":"2023","author":"Rejeski","year":"2023","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"10.1016\/j.critrevonc.2026.105553_bib51","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood.2025028833","article-title":"T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy","volume":"146","author":"Rejeski","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105553_bib52","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1055\/a-2528-5071","article-title":"Checkpoint inhibitors, CAR T cells, and the hemostatic system: what do we know so far?","volume":"45","author":"Rolling","year":"2025","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.critrevonc.2026.105553_bib53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1538-7836.2006.02267.x","article-title":"Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial","volume":"5","author":"Saito","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.critrevonc.2026.105553_bib54","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jth.14015","article-title":"Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH","volume":"16","author":"Samuelson Bannow","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.critrevonc.2026.105553_bib55","doi-asserted-by":"crossref","first-page":"8349","DOI":"10.3390\/ijms24098349","article-title":"Thrombotic events are unusual toxicities of chimeric antigen receptor T-cell therapies","volume":"24","author":"Schorr","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105553_bib56","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1160\/TH14-09-0731","article-title":"VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP","volume":"113","author":"Schwameis","year":"2015","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.critrevonc.2026.105553_bib57","first-page":"3153","article-title":"Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction","volume":"141","author":"Selli","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105553_bib58","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1160\/TH08-03-0147","article-title":"Metabolism and cell biology of vitamin K","volume":"100","author":"Shearer","year":"2008","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.critrevonc.2026.105553_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215920","article-title":"Hematologic cytopenia post CAR T cell therapy: etiology, potential mechanisms and perspective","volume":"550","author":"Si","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105553_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.bvth.2025.100105","article-title":"Comprehensive assessment of endothelial dysfunction before cellular therapy: EASIX, local imaging, and systemic biomarkers","volume":"2","author":"Simons","year":"2025","journal-title":"Blood Vessel. Thromb. Hemost."},{"key":"10.1016\/j.critrevonc.2026.105553_bib61","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1538-7836.2011.04232.x","article-title":"The chemotherapy metabolite acrolein upregulates thrombin generation and impairs the protein C anticoagulant pathway in animal-based and cell-based models","volume":"9","author":"Swystun","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.critrevonc.2026.105553_bib62","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1055\/s-0037-1616068","article-title":"Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation","volume":"86","author":"Taylor","year":"2001","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.critrevonc.2026.105553_bib63","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2019.5358","article-title":"Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the SCARLET randomized clinical trial","volume":"321","author":"Vincent","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2026.105553_bib64","doi-asserted-by":"crossref","first-page":"15","DOI":"10.32607\/actanaturae.11503","article-title":"Neutrophil extracellular traps (NETs): opportunities for targeted therapy","volume":"13","author":"Volkov","year":"2021","journal-title":"Acta Nat."},{"key":"10.1016\/j.critrevonc.2026.105553_bib65","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.bbmt.2019.11.027","article-title":"Coagulation disorders after chimeric antigen receptor T cell therapy: analysis of 100 patients with relapsed and refractory hematologic malignancies","volume":"26","author":"Wang","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2026.105553_bib66","article-title":"Low-dose administration of prednisone has a good effect on the treatment of prolonged hematologic toxicity post-CD19 CAR-T cell therapy","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105553_bib67","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbae104","article-title":"Meta-DHGNN: method for CRS-related cytokines analysis in CAR-T therapy based on meta-learning directed heterogeneous graph neural network","volume":"25","author":"Wei","year":"2024","journal-title":"Brief. Bioinform"},{"key":"10.1016\/j.critrevonc.2026.105553_bib68","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1049","article-title":"Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105553_bib69","first-page":"CD007871","article-title":"Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults or children with bleeding","volume":"2016","author":"Wikkels\u00f8","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.critrevonc.2026.105553_bib70","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12865-017-0213-0","article-title":"IgM\u03ba paraprotein from gammopathy patient can bind to cardiolipin and interfere with coagulation assay: a case report","volume":"18","author":"Wu","year":"2017","journal-title":"BMC Immunol."},{"key":"10.1016\/j.critrevonc.2026.105553_bib71","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2026.105553_bib72","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105553_bib73","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1182\/bloodadvances.2022007454","article-title":"Relative hypercoagulation induced by suppressed fibrinolysis after tisagenlecleucel infusion in malignant lymphoma","volume":"6","author":"Yamasaki-Morita","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105553_bib74","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010080","article-title":"Uncommon biphasic CAR-T expansion induces hemophagocytic lymphohistiocytosis-like syndrome and fatal multiple infections following BCMA CAR-T cell therapy: a case report","volume":"12","author":"Yan","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105553_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1692892","article-title":"Machine learning-based predictive model for high-grade cytokine release syndrome in chimeric antigen receptor T-cell therapy","volume":"16","author":"Yu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105553_bib76","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/bloodadvances.2024014027","article-title":"EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients after CD19-CAR T-cell therapy","volume":"9","author":"Zandaki","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105553_bib77","first-page":"144","article-title":"Risk factors of tumor lysis syndrome in relapsed\/refractory multiple myeloma patients undergoing BCMA CAR-T cell therapy","volume":"51","author":"Zhang","year":"2022","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:45:52Z","timestamp":1793087152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826004403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":77,"alternative-id":["S1040842826004403"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105553","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-T cell therapy-associated coagulopathy: From immunothrombotic storm mechanisms to precision management strategies","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105553","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105553"}}